Overview

Brandon’s principal area of practice is complex commercial litigation.

Experience

  • Defending officers and directors of E&P company in putative securities class action under Section 10(b) of the Exchange Act

  • Defending payroll software company and its officers and directors in putative securities class action under Section 10(b) of the Exchange Act

  • Defending software company and its officers and directors in derivative litigation alleging federal securities and breach of fiduciary duty claims

  • Representing clients in the Delaware Superior Court and Delaware Supreme Court over a disputed membership interest purchase agreement

  • Represented nuclear medicine company in a DOJ investigation and obtained a rare declination of charges

  • Represented hedge fund in litigation in federal court against public company that rejected nominations of candidates for director elections under an advance notice bylaw, resulting in favorable settlement of proxy campaign

  • Counsel for two hedge funds in an expedited nine-witness trial in the Delaware Court of Chancery over a disputed multi-billion dollar stock authorization by a public company

  • Defended public company and its directors and officers in litigation against activist investment fund alleging breach of fiduciary duty claims

Credentials

Education

  • University of Virginia School of Law, J.D., 2022
  • Florida State University, B.S., Economics and Political Science, 2019

Admissions

  • District of Columbia
  • New York
Insights

Client Alerts

Delaware Supreme Court’s Earnout Decision Reinforces Primacy of Contract and Illustrates the Limits of the Implied Covenant

On January 12, 2026, the Delaware Supreme Court issued an en banc opinion in Johnson & Johnson v. Fortis Advisors LLC, No. 490, 2024, 2026 WL 89452 (Del. Jan. 12, 2026), largely affirming and reversing in part a Court of Chancery post-trial decision that awarded former stockholders of Auris Health, Inc. (“Auris”) over $1 billion in damages in their post-closing earnout dispute against Johnson & Johnson (“J&J”).

January 22, 2026

January 22, 2026 • 9-minute read